Rifaximin suspension mix granule formulation

A rifaximin and dry suspension technology, applied in the field of medicines, can solve the problems of unpleasant treatment swallowing, difficult to swallow, narrow field, etc., and achieve the effects of improving the bioavailability of medicines, being convenient to swallow, and having a large contact area.
CN1485034AInactive Publication Date: 2004-03-31天津合益达生物医学技术有限公司

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
天津合益达生物医学技术有限公司
Publication Date
2004-03-31
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

A dried rifaximin suspensoid pelletized granule, which is prepared by mixing rifaximin as the active component and medicinal auxiliary materials at the weight ratio of 1í†5í½35. The medicinal auxiliary materials mainly comprise the suspending agent and the flocculating agent at the weight ratio of 1í†0.05í½2. The suspending agent comprises two or three of microcrystal cellulose, methylcellulose, sodium methylol cellulose, hydroxypropyl methylcellulose, sodium alginate, gum arabic and pectine. The flocculating agent is one of citrate, tartrate, phosphate and aluminum chloride. Other auxiliary materials contain cane sugar, starch, food sweetening agent, preservative and flavoring and so on.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of medicines, in particular to a rifaximin dry suspension granule capable of treating intestinal diseases. Background technique

[0002] Rifaximin is a new type of antibiotic widely used among rifamycin derivatives. It can be used to treat acute and chronic intestinal infections caused by Gram-positive bacteria and Gram-negative bacteria, and can be used as a therapeutic agent for hyperammonia. Auxiliary drugs. This drug has a broad antibacterial spectrum and has antibacterial effects on aerobic or anaerobic bacteria in the gastrointestinal tract. Its biggest feature is that it is neither absorbed by the intestinal tract nor purified by gastric juice, that is, this product is almost not absorbed systematically, and the drug concentration cannot be detected in the urine and tissues of patients after taking it, but is only excreted in its original form through the large intestine. Therefore, its toxic and side effects...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More